The global implantable drug delivery devices market is expected to grow at a moderate CAGR of ~8% during the forecast period, i.e., 2022-2030. The growth of the market can be attributed to the increasing prevalence of chronic diseases globally, such as cardiovascular diseases, auto-immune diseases, diabetes, and others. Additionally, the growing number of aging populations in various countries has increased the risk of getting chronic diseases. As a result, there is an increasing influx of patients for surgeries using implantable drug delivery devices, which is estimated to boost the market growth. According to World Health Organization (WHO), in 2020, approximately 10 million individuals have died due to cancer, and it has been recognized as the leading cause of death globally. Rising concern among governmental organizations for developing better medical devices to provide high-level safety standards to the patients has created significant growth opportunities for the implantable drug delivery device market over the forecast period. Moreover, the growing preference of the patients for drug delivery device products on the back of its high efficiency has also contributed towards the global market growth. CLICK TO DOWNLOAD SAMPLE REPORT
The market is segmented on the basis of products into contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular implants, infusion pumps, and others, out of which, the drug-eluting stents segment is expected to dominate the global market during the forecast period, in terms of revenue, on account of increasing implementations of these implants in the medical industry for various indications such as cancer treatment, contraception, hormone regulation, and others.
Based on type, the biodegradable products segment is expected to witness significant growth over the forecast period in the market on the back of the its advantages over non-biodegradable products, which includes easy absorption, fabrication, and excretion of inter-polymers, greater acceptance rate, positive outcome, and others.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia-Pacific region is estimated to exhibit exponential growth over the forecast period, on account of the steadily increasing healthcare expenditure and rising concern & awareness for the development of advanced devices in the region. Additionally, the rising population among Asian countries such as China, India, and others has significantly increased the disease prevalence rate and patient influx in the hospitals and other healthcare service providers, which is expected to further boost the market growth in the region.
Furthermore, in 2022, the market in North America region held the highest shares in the global market, on the back of increasing investments by the private and governmental organizations to develop advanced implantable drug delivery devices owing to the increasing cases of cancer, diabetes, cardiovascular diseases, and others. Additionally, major implantable drug delivery product manufacturers in the North American market have increased the market’s growth.
The global implantable drug delivery devices market is further classified on the basis of region as follows:
Our in-depth analysis of the global implantable drug delivery devices market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Emergence of novel products and increasing incidence of chronic diseases are the key factors driving market growth.
The market is anticipated to attain a moderate CAGR of ~8% over the forecast period, i.e., 2022-2030.
High cost of implantable drug delivery devices and string government regulations are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the growing population and rising incidence of chronic disorders.
The major players dominating the Implantable Drug Delivery Devices market are Boston Scientific Corporation, Merck & Co., Inc., Medtronic Plc, Allergan, Inc., Abbott Laboratories, DSM Biomedical, Varian Medical Systems, Inc., and others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, type, application, end-user, and region.
With respect to type, the non-biodegradable segment is anticipated to hold the largest market share on the back of increasing adoption of polymeric matrix-based systems in the medical field.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization